An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

A new type of off-the-shelf cell-based immunotherapy shows promise for B-cell lymphomas, and could make make future cellular ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

Researchers sought to determine whether CNS bridging radiotherapy would improve responses to CAR-T therapy in patients with B-cell lymphomas.

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...

Roche (RHHBY) announced that it has received 510(k) clearance from the FDA for its highly-sensitive in-situ hybridisation test, the Ventana ...